|
Canada-0-BAILIFFS Azienda Directories
|
Azienda News:
- Accueil - Vivet Therapeutics
Vivet’s team is dedicated to bringing hope and transformative gene therapies to patients living with rare genetic disorders By developing a unique pipeline of liver-directed AAV products and pioneering new technologies, we strive to unlock life-changing treatments for those in need
- Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1 2 GATEWAY . . .
Paris, France, April 8, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces that it has dosed its first patient with its lead program VTX-801 in Cohort 2 of its ongoing GATEWAY Clinical Trial for the treatment
- Wilson’s disease - Vivet Therapeutics
VTX-801 Wilson disease (WD) is an orphan, inherited, progressive and severely debilitating disorder of copper metabolism which is lethal if left untreated Cause : Wilson disease is associated with tissue accumulation of copper, as a result of mutations in the ATP7B copper transporter ATP7B has 2 central roles in copper metabolism : Excretion of excess […]
- Vivet Therapeutics to Present Key Findings on its Gene Therapy Program . . .
Paris, France, November 14, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotechcompany developing novel and long-lasting gene therapies for rare inherited liver metabolicdisorders, today announces that it will be presenting key pre-clinical findings for VTX-806, itsgene therapy program for the treatment of Cerebrotendinous Xanthomatosis (CTX), at TheLiver Meeting presented by
- News - Vivet Therapeutics
Paris, France, November 14, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotechcompany developing novel and long-lasting gene therapies for rare inherited liver metabolicdisorders, today
- Study on Treatment of Wilson Disease in Japan Published in Japanese . . .
Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the publication of a peer reviewed paper titled ‘Treatment of Wilson Disease in Japan: An Insurance Claims Database Study’ in the
- Vivet Therapeutics presents interim data on its Phase 1 2 GATEWAY trial . . .
Vivet Therapeutics Presents Interim Data from its Phase 1 2 GATEWAY Trial for the Treatment of Wilson Disease at EASL Congress 2024 VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology Encouraging safety and tolerability with no serious adverse events reported Paris, France, June 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company
- The @European Commission has granted Orphan Drug Designation (#ODD) to . . .
Paris, France, September 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces that the European Commission has granted Orphan Drug Designation (ODD) to VTX-806, its gene therapy product for the treatment of
- Investors - Vivet Therapeutics
With nearly €500 million in assets under management and more than 45 investments made since its launch in 2009, Kurma Partners has built up strong and widely recognized expertise in the financing of innovation in the health care sector and in biotechnology, from pre-seed to growth capital, through its Kurma Biofund and Kurma Diagnostics funds Its team of 13 investors is managed by five
- Vivet Therapeutics Presents Breakthrough Data on AAV Neutralizing . . .
Sevilla, October 2025 – At the 32nd Annual Congress of the European Society of Gene Cell Therapy (ESGCT), Vivet Therapeutics shared new clinical data with its VTX-PID proprietary imlifidase formulation, highlighting the effective reduction of neutralizing antibodies (NAbs) against AAV3B in healthy volunteers Key Findings: Vivet Therapeutics remains committed to advancing innovative
|
|